TR201903312T4 - Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. - Google Patents

Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. Download PDF

Info

Publication number
TR201903312T4
TR201903312T4 TR2019/03312T TR201903312T TR201903312T4 TR 201903312 T4 TR201903312 T4 TR 201903312T4 TR 2019/03312 T TR2019/03312 T TR 2019/03312T TR 201903312 T TR201903312 T TR 201903312T TR 201903312 T4 TR201903312 T4 TR 201903312T4
Authority
TR
Turkey
Prior art keywords
methods
benralizumab
asthma exacerbation
exacerbation rates
reduce asthma
Prior art date
Application number
TR2019/03312T
Other languages
English (en)
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR201903312T4 publication Critical patent/TR201903312T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Burada bir astım hastasında astım alevlenmelerini azaltma yöntemleri sağlanmakta olup, hastaya etkili bir miktarda anti-interlökin-5 reseptörü (IL-5R) antikor benralizumab veya bunun bir antijen bağlayıcı fragmanının verilmesini içerir.
TR2019/03312T 2013-08-12 2014-08-07 Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. TR201903312T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12

Publications (1)

Publication Number Publication Date
TR201903312T4 true TR201903312T4 (tr) 2019-04-22

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03312T TR201903312T4 (tr) 2013-08-12 2014-08-07 Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.

Country Status (25)

Country Link
US (2) US9441037B2 (tr)
EP (1) EP3033101B1 (tr)
JP (3) JP6746495B2 (tr)
KR (2) KR20220057637A (tr)
CN (2) CN111588848A (tr)
AU (2) AU2014306956B2 (tr)
BR (1) BR112016002401A8 (tr)
CA (1) CA2918105C (tr)
CY (1) CY1122132T1 (tr)
DK (1) DK3033101T3 (tr)
ES (1) ES2716906T3 (tr)
HK (2) HK1221644A1 (tr)
HR (1) HRP20190405T1 (tr)
HU (1) HUE042607T2 (tr)
LT (1) LT3033101T (tr)
ME (1) ME03348B (tr)
MX (1) MX368508B (tr)
PL (1) PL3033101T3 (tr)
PT (1) PT3033101T (tr)
RS (1) RS58404B1 (tr)
RU (1) RU2676333C2 (tr)
SG (2) SG10202005560UA (tr)
SI (1) SI3033101T1 (tr)
TR (1) TR201903312T4 (tr)
WO (1) WO2015023504A1 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3520811T3 (da) * 2013-08-12 2021-03-22 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
AU2014334563A1 (en) * 2013-10-15 2016-04-07 Astrazeneca Ab Methods for treating Chronic Obstructive Pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
RU2019118984A (ru) 2014-01-10 2019-08-06 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
WO2017077391A2 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3565823A1 (en) 2017-01-04 2019-11-13 Apitope International NV S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｉｌ－５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
WO2011062984A1 (en) * 2009-11-18 2011-05-26 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
BR112013013460A8 (pt) * 2010-12-16 2019-02-12 Genentech Inc métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
KR20140097217A (ko) 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
DK3520811T3 (da) * 2013-08-12 2021-03-22 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
CN111617244A (zh) 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
AU2020201327A1 (en) 2020-03-12
US20150044202A1 (en) 2015-02-12
MX368508B (es) 2019-10-07
CN111588848A (zh) 2020-08-28
PL3033101T3 (pl) 2019-06-28
LT3033101T (lt) 2019-03-25
KR20220057637A (ko) 2022-05-09
AU2014306956A1 (en) 2016-02-04
AU2014306956B2 (en) 2019-11-21
BR112016002401A2 (pt) 2017-09-12
ME03348B (me) 2019-10-20
JP2020128375A (ja) 2020-08-27
JP2022120009A (ja) 2022-08-17
ES2716906T3 (es) 2019-06-17
EP3033101A1 (en) 2016-06-22
RU2016108723A3 (tr) 2018-06-18
EP3033101B1 (en) 2018-12-19
HK1225302B (zh) 2017-09-08
DK3033101T3 (en) 2019-04-08
EP3033101A4 (en) 2017-07-12
HRP20190405T1 (hr) 2019-04-19
RS58404B1 (sr) 2019-04-30
RU2016108723A (ru) 2017-09-19
BR112016002401A8 (pt) 2018-06-12
CA2918105C (en) 2023-02-28
HK1221644A1 (zh) 2017-06-09
SG10202005560UA (en) 2020-07-29
US20170198049A1 (en) 2017-07-13
PT3033101T (pt) 2019-04-02
HUE042607T2 (hu) 2019-07-29
CN105451760A (zh) 2016-03-30
WO2015023504A8 (en) 2015-09-24
KR102390714B1 (ko) 2022-04-26
RU2676333C2 (ru) 2018-12-28
WO2015023504A1 (en) 2015-02-19
MX2016001383A (es) 2016-08-03
CY1122132T1 (el) 2020-11-25
CA2918105A1 (en) 2015-02-19
KR20160042121A (ko) 2016-04-18
JP2016527324A (ja) 2016-09-08
SI3033101T1 (sl) 2019-04-30
JP6746495B2 (ja) 2020-08-26
SG11201600481UA (en) 2016-02-26
US9441037B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
CY1122278T1 (el) Αντι il-36r αντισωματα
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201492101A1 (ru) Антитела против fcrn
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
PH12014502406B1 (en) Anti-il-23p19 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
PH12016501366A1 (en) Novel anti-baff antibodies
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
TN2014000207A1 (en) Anti il-36r antibodies